OGSIVEO (nirogacestat) should be administered as 150 mg orally twice daily for the treatment of progressing desmoid tumors.

Dosage Information:

OGSIVEO is prescribed at an initial dosage of 150 mg orally, twice daily. Treatment continues until either disease progression or the occurrence of unacceptable toxicity. This dosage is designed to optimize therapeutic outcomes while minimizing the risk of adverse reactions. For patients experiencing severe adverse effects, dosage modifications may be necessary, as specified in the full prescribing information. It is important to monitor patients regularly for signs of toxicity, and adjustments to the dosage should be made accordingly.